학술논문
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma
Document Type
Article
Author
Martínez-Cibrián, N.; Ortiz-Maldonado, V.; Blázquez, A.; Magnano, L.; Giné, E.; Correa, J.G.; Mozas, P.; Rodríguez-Lobato, L.G.; Rivero, A.; Montoro-Lorite, M.; Ayora, P.; Brillembourg, H.; de Larrea, C.F.; López-Guillermo, A.; Urbano-Ispizua, Á.; Delgado, J.; Español-Rego, M.; Cid, J.; Lozano, M.; Navarro, S.; Castellà, M.; Benítez-Ribas, D.; Varea, S.; Olesti, E.; Guillén, E.; Sáez-Peñataro, J.; Pascal, M.; Juan, M.; Alserawan, L.; González-Navarro, E.A.; Sánchez-Castañón, M.; Cabezón, R.; Setoaín, X.; Rodríguez, S.
Source
In: British Journal of Haematology . (British Journal of Haematology, February 2024, 204(2):525-533)
Subject
Language
English
ISSN
13652141
00071048
00071048